current glp 1 drugs GLP-1 Agonists Explained: Definition, How They Work, Side Effects The GLP-1 Agonists and Obesity:

Mean change in body weight was the trials primary endpoint

Some case reports show that GLP-1RA treatment initiation in patients leads to worsened Pso lesions, possibly because the drug triggers immune dysregulation, which results in increased pro-inflammatory pathways [19,65]

The dual action of Tirzepatide effectively reduces caloric intake while improving glucose metabolism, which explains why the SURMOUNT-1 trial data showed up to a 22.5% mean weight reduction at the 72-week mark

doi: 10.1517/14656566.2013.838559

Many experts are now looking beyond the BMI for insights into defining obesityand how to treat it

Trujillo, J.M., Nuffer, W., and Smith, B.A